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Infrared vibrational spectroscopy: 
a rapid and novel diagnostic and 
monitoring tool for cystinuria
Katherine V. Oliver1, Annalisa Vilasi2, Amandine Maréchal1, Shabbir H. Moochhala3, 
Robert J. Unwin3 & Peter R. Rich1
Cystinuria is the commonest inherited cause of nephrolithiasis (~1% in adults; ~6% in children) and 
is the result of impaired cystine reabsorption in the renal proximal tubule. Cystine is poorly soluble 
in urine with a solubility of ~1 mM and can readily form microcrystals that lead to cystine stone 
formation, especially at low urine pH. Diagnosis of cystinuria is made typically by ion-exchange 
chromatography (IEC) detection and quantitation, which is slow, laboursome and costly. More rapid 
and frequent monitoring of urinary cystine concentration would significantly improve the diagnosis 
and clinical management of cystinuria. We used attenuated total reflection - Fourier transform infrared 
spectroscopy (ATR-FTIR) to detect and quantitate insoluble cystine in 22 cystinuric and 5 healthy 
control urine samples. Creatinine concentration was also determined by ATR-FTIR to adjust for urinary 
concentration/dilution. Urine was centrifuged, the insoluble fraction re-suspended in 5 μL water 
and dried on the ATR prism. Cystine was quantitated using its 1296 cm−1 absorption band and levels 
matched with parallel measurements made using IEC. ATR-FTIR afforded a rapid and inexpensive 
method of detecting and quantitating insoluble urinary cystine. This proof-of-concept study provides a 
basis for developing a high-throughput, cost-effective diagnostic method for cystinuria, and for  
point-of-care clinical monitoring
Cystinuria is an autosomal inherited aminoaciduria caused by mutations in one or both subunits of the amino 
acid transport system b0,+, and has a global prevalence ranging from 1 in 2000 to 1 in 100000, depending on the 
population1. It results in a failure to reabsorb freely filtered cystine in the proximal tubule of the kidney, causing 
increased urinary excretion of cystine and the dibasic amino acids; lysine, arginine and ornithine2. Cystine is a 
dimer of cysteine formed by oxidation of their sulphydryl groups to form a disulphide bond. It is poorly soluble 
in water in the physiological pH range3. Its solubility limit in urine is ~1 mM1,4 and it forms a microcrystalline 
precipitate above this limit. This insoluble cystine can form recurrent stones that may cause kidney obstruction 
and lead eventually to irreversible damage and loss of function. Total cystine levels in cystinuric patients typically 
range from 1 to 2 mM, but concentrations over 4 mM have been reported5. Patients with urinary cystine concen-
trations above the solubility limit have a significantly increased risk of stone formation1,2. Many patients respond 
to simple measures such as increased fluid intake, urinary alkalinisation, an alkaline ash or low methionine 
(animal protein) diet, and dietary salt restriction6. Dithiol drugs can also decrease urinary cystine by disulphide 
bond reduction and formation of more soluble drug-cysteine complexes. However, these measures do not treat 
the underlying cause of the disease and are most effective when used prophylactically1. Once stone formation has 
occurred, shock-wave lithotripsy or surgery is usually required.
Cystinuria is commonly diagnosed by measuring urinary cystine1. Early diagnosis and preventive mainte-
nance therapy are essential and require a means to detect and quantitate cystine repeatedly. Qualitative color-
imetric screening tests are available, but these have low specificity7,8. Derivatisation followed by ion exchange 
chromatography (IEC) is the current clinical gold standard for amino acid analyses, including cystine7. However, 
IEC is time-consuming and expensive in personnel and equipment. As a result, it is not generally available at the 
point-of-care. Alternatively, urinary cystine solubility threshold can be quantitated by a cystine capacity assay9, 
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but again this is labour-intensive and not widely available. A faster, simpler and more cost-effective routine 
method for quantitating urinary cystine would be of significant clinical value for both diagnosis and monitoring 
of cystinuria.
Fourier transform infrared (FTIR) vibrational spectroscopy is a powerful chemical analytical technique. It 
can provide rapid, quantitative and reproducible analyses of multiple components in complex mixtures10 and 
thus provides an alternative means for quantitative evaluation of some clinical biomarkers. Data collection has 
been greatly simplified with robust attenuated total reflection (ATR) microprisms that allow FTIR spectra to be 
obtained simply by placing the test material on the surface of the ATR prism11. Many types of molecule are infra-
red active and have unique patterns of absorbance; hence, IR spectra of biological materials are potentially rich in 
information, but can be complex and difficult to deconvolute. IR analysis of the composition of kidney stones is 
already used clinically12–14 and has been applied to cystine stones15. There is also a rapidly expanding literature on 
analyses of levels of specific constituents in complex biological fluids such as urine16–20 and blood16,21,22 and, with 
2D imaging methods, mapping of different cell types in normal and diseased tissue sections23–27, including kid-
ney28,29. In this report we explore the potential of ATR-FTIR spectroscopy as a rapid, reagent-free clinical method 
for detecting and quantitating insoluble cystine in urine.
Results
Quantitation of urea and creatinine in urine by ATR-FTIR spectroscopy. Variations in both fluid 
intake and glomerular filtration rate (GFR) affect the concentrations of materials excreted in urine. Creatinine 
is a breakdown product of creatine phosphate in muscle and is normally formed at a fairly constant rate that is 
dependent on muscle mass. Hence, its concentration in urine is a good indicator of overall urine dilution and 
concentrations of other components are commonly factored by creatinine concentration to allow for urinary 
concentration/dilution.
Urinary creatinine and urea were determined by deconvolution of the 1510–1445 cm−1 region of undried 
urine FTIR absorbance spectra as described in Methods. Figure S3 shows an example of the deconvolution and 
of a typical ATR-FTIR spectrum of urine from a cystinuric patient. Figure S4 summarises the urea and creatinine 
concentrations determined by this method in urine samples from 22 cystinuric patients (labelled from P1 to P24) 
and 5 healthy controls. Urea concentrations were 28–443 mM and creatinine concentrations were < 1–20 mM, 
values within the typical range. As expected, the concentrations of urea and creatinine tend to correlate and no 
ratio difference between cystinuric and healthy samples was evident.
Comparison of ATR-FTIR and Jaffe methods of creatinine quantitation. To validate the ATR-FTIR 
method for urinary creatinine quantitation, creatinine concentrations in the same urine samples were also deter-
mined with the Jaffe reaction, the most widely used clinical method30,31. A reasonable correlation was observed 
between the two methods (Fig. 1A) with a Pearson correlation coefficient, r, of 0.75, despite two outliers (indi-
cated with stars). A Bland-Altman analysis32 was also performed to establish the similarity between the results 
generated by the two methods (Fig. 1B). The dashed line shows the mean bias and the dotted lines show 95% 
confidence limits. The mean bias was 1.4 mM, demonstrating that the Jaffe reaction tended to indicate higher 
creatinine concentrations. All data points apart from the two outliers fell within the 95% confidence limits. The 
origin of the differences in concentrations predicted by the Jaffe and ATR-FTIR methods in the two outliers was 
not investigated further. However, for the most extreme outlier, the 30 mM value determined by the Jaffe reaction 
(12.5 mM with ATR-FTIR) appeared to be much higher than expected given the 275 mM urea concentration in 
this same urine sample.
Quantitation of cystine by ATR-FTIR spectroscopy. The ATR-FTIR spectrum of dried L-cystine 
is shown in Fig. 2A. A calibration plot (Fig. 2B) was generated from differences in intensities at 1296 minus 
1280 cm−1 of the second derivatives of absorbance spectra of dried 5 μ L aliquots of 0 to 3 mM cystine suspensions. 
Figure 1. Comparison of the Jaffe and ATR-FTIR methods of creatinine quantitation. (A) Plot of urinary 
creatinine concentrations determined by the Jaffe (Y axis) and ATR-FTIR (X axis) methods. (B) Bland-Altman plot of 
the same data. Circles: samples for which cystine content was also determined; squares: additional urine samples.
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A linear line of best fit through the origin was a reasonable fit in this concentration range, confirming that even 
the highest cystine levels result in a layer that remains within the active spectroscopic volume delineated by the 
depth of penetration of the evanescent wave11. This is consistent with the cystine molecular volume of 193 Å3 and 
an active spectroscopic volume of height ~1 micron and diameter 3 mm, which would accommodate ~60 nmoles 
cystine (i.e. equivalent to 5 μ L of a 12 mM cystine suspension).
Although drying of urine samples onto the ATR prism considerably increases the intensities of absorbance 
bands of cystine, absorbance bands of other components will also be amplified. These could mask some cystine 
bands, or might increase the layer thickness beyond the evanescent wave limit. Because of this, and because the 
clinically important parameter is the insoluble cystine, a protocol was developed which measured the insoluble 
components after removal of the majority of soluble material. This was achieved by centrifugation of urine sam-
ples to form a pellet of the insoluble components that could be separated from supernatant that contained the 
solutes. Pellets were resuspended in water and aliquots were dried onto the prism and absorbance spectra were 
recorded. The characteristic band pattern of cystine (Fig. 2A, dashed line) could clearly be seen in the spectra 
of most of the dried, insoluble fractions derived from cystinuric patient urine (Fig. 2A, solid line) and could be 
quantitated using the calibration plot (Fig. 2B). Hence, this establishes proof of concept that insoluble cystine 
at levels present in cystinuric patient urine samples can indeed be detected and quantitated using ATR-FTIR 
technology.
The concentrations of insoluble cystine in 22 cystinuric and 5 healthy control patient urine samples were ana-
lysed (Fig. 3) using this protocol. Seventeen of the cystinuric patient samples had detectable insoluble cystine of 
up to 3.1 mM. Five cystinuric patient samples and all healthy controls had no detectable insoluble cystine, indicat-
ing that their urinary cystine concentrations were below the solubility limit of ~1 mM. In order to accommodate 
variations in urine concentrations, the insoluble cystine values were also ratioed to the ATR-FTIR-determined 
creatinine concentrations (Fig. 4).
Figure 2. Absorbance spectra of cystine and insoluble cystinuric urine. (A) Dry cystine (dashed line) and 
a dried insoluble fraction of a cystinuric urine sample (solid line). (B) Calibration curve for pure cystine based 
on the differences in intensities at 1296 cm−1 minus 1280 cm−1 of their second derivative spectra. A linear fit 
through the origin was calculated with no error weighting.
Figure 3. Insoluble cystine in urine samples determined by ATR-FTIR spectroscopy. Insoluble cystine was 
determined by the ATR-FTIR method described in the text in cystinuric (Pn) and control (Nn) urine samples. 
Samples were measured in triplicate and error bars represent standard error of mean.
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Comparison of FTIR and clinical methods of cystine quantitation. The cystine concentrations 
determined by ATR-FTIR spectroscopy were compared with those obtained by the clinical gold standard of ion 
exchange chromatography after derivatisation. The ATR-FTIR method measures only insoluble cystine, which is 
the clinically relevant fraction, whilst the clinical method reports total (soluble + insoluble cystine). Hence, for 
a comparison of the total cystine obtained by the two methods, an offset of 1 mM (solubility limit for cystine) 
was added to those values obtained by ATR-FTIR that had measureable insoluble cystine to allow for the ~1 mM 
soluble cystine fraction that must have been present in the original urine samples. For samples which showed no 
ATR-FTIR-detected insoluble cystine, their cystine must have been below the 1 mM solubility limit and so have 
been plotted as 0.5 ± 0.5 mM. Figure 5A shows that there was a good correlation between the results obtained 
by the two methods (Pearson correlation coefficient, r, of 0.915). A Bland-Altman analysis32 of the same data 
(Fig. 5B) indicated little or no bias between the methods and data points fell within the 95% confidence limits.
Discussion
The purpose of this study was to assess whether ATR-FTIR spectroscopy could provide a novel quantitative 
method for easier cystinuria diagnosis and routine monitoring of urinary cystine that is fast and cost-effective 
in comparison with the ‘gold-standard’ of IEC. We focused on the quantitation of the insoluble cystine fraction, 
which can easily be separated from possible interfering soluble components, because it is this insoluble material 
that promotes stone formation and disease complications in cystinuric patients.
To allow for large differences in urine sample dilutions, the insoluble cystine concentrations were ratioed to uri-
nary creatinine concentrations that were also determined by ATR-FTIR spectroscopy. These ATR-FTIR-derived cre-
atinine concentrations were validated by comparison with values obtained by the clinical standard Jaffe reaction. A 
reasonable correlation between the two methods was found, though the Jaffe reaction tended to give slightly higher 
Figure 4. Insoluble cystine:creatinine ratios in urine determined by ATR-FTIR spectroscopy. Urinary 
cystine:creatinine ratios (μ M:mM) were calculated from creatinine and insoluble cystine levels determined by 
the ATR-FTIR methods described in the text in cystinuric (Pn) and control (Nn) urine samples. Samples were 
measured in triplicate and error bars represent standard error of mean.
Figure 5. Comparison of the ion exchange chromatographic and ATR-FTIR methods of cystine 
quantitation. (A) Plot of urinary cystine concentrations determined by the IEC (Y axis) and ATR-FTIR (X axis) 
methods. (B) Bland-Altman plot of the same data. A 1 mM offset has been added to the ATR-FTIR values to 
account for the soluble cystine since it measures only the insoluble cystine (see text for details).
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values. This could be a result of additional chromogens in urine that interfere with the Jaffe method30,33,34. For all but 
two samples, the concentrations derived by the two methods fell within the 95% confidence interval32.
Sufficiently accurate quantitation of the insoluble urinary cystine was also achieved by ATR-FTIR spectros-
copy, using intensities at 1296 minus 1280 cm−1 in the second derivative spectra of the dried, insoluble fractions 
derived from the urine samples. These wavenumbers were chosen because there is no other strong contributor 
from other insoluble components (for example, oxalate, urate and dihydroxyadenine) that might be present in 
urine from patients with different kidney stone-related conditions. A linear line through the origin (Fig. 2b) of 
a calibration plot with pure cystine was a reasonable fit to at least 3 mM cystine, which covers the typical range 
of the cystinuric urine samples. The cystine levels measured by the ATR-FTIR spectroscopy were validated by 
parallel IEC measurements. However, the FTIR protocol described here measures only the insoluble cystine, whilst 
the IEC method measures total cystine without specifying soluble and insoluble fractions. Hence, for comparison 
of the two methods, a nominal 1 mM soluble cystine was added to the IR-determined insoluble cystine values in 
order to allow direct comparison to the IEC-determined total (soluble plus insoluble) cystine estimates.
Consistent with the IEC measurements, the ATR-FTIR method revealed that 17 of the 22 cystinuric patient 
samples had urinary cystine above its solubility threshold, whereas none of the control samples has detectable 
insoluble cystine. Since all of the cystinuric patients included in this study were being advised on their fluid intake 
and diet, and some were receiving drug treatment (Table S1), it could be expected that this management may have 
resulted in clearance of insoluble cystine in some instances. Indeed, four of the five cystinuric patients with no 
FTIR-detectable insoluble cystine (P5, P13, P20 and P23) were receiving cystine-decreasing therapies. A fifth, P3, 
also had no FTIR-detectable insoluble cystine, but was not on drug treatment and the creatinine concentration 
was not particularly low, suggesting that this patient suffered from only mild cystinuria. Of the six cystinuric 
patients with relatively low (< 0.5 mM) FTIR-detected insoluble cystine (P7, P8, P11), three were also receiving 
cystine-decreasing therapies; two also (P14 and 24) had low creatinine suggesting dilute urine samples; one (P22) 
had low insoluble urinary cystine with moderate/high creatinine despite no drug treatment. In contrast, high levels 
of cystine were recorded in P1, P6, P15, P18 and P19; these patients were either not receiving drug treatment for 
cystinuria (P6, P15 and P19) and/or had concentrated urine as judged by relatively high creatinine concentrations 
(P1, P15 and P18). The above considerations emphasise the point that, when assessing stone formation risk from 
these data, a more useful clinical parameter may be the cystine:creatinine (Fig. 4). For example, P1 and P18 had 
comparatively high insoluble cystine concentrations, but P1 had a much higher insoluble cystine:creatinine ratio, 
suggesting that this patient might have a more severe form of cystinuria. Similarly, although P14 had relatively 
low insoluble cystine, the cystine:creatinine ratio suggested that the level could be of more serious concern. It 
might be emphasised that essentially the same diagnoses result from the more time-consuming and expensive 
IEC analyses of the same samples.
In summary, we demonstrate proof-of-concept of a simple FTIR method to detect insoluble cystine levels 
across the mild to severe levels that are found in most cystinuric patients, based on its 1296 cm−1 absorbance band 
in spectra of dried insoluble fractions of urine samples. Although the FTIR method provides an estimate for insol-
uble cystine that is comparable to data obtained by the IEC clinical standard method, it must be emphasised that 
the protocol as described provides a measure only of insoluble cystine, whereas the IEC method provides quan-
titative information on total cystine, together with a wide range of amino acids. Nevertheless, the cost of suitable 
equipment for the FTIR method is considerably less than that required for IEC, especially if the processing time 
and labour costs are included. Furthermore, the FTIR method requires minimal expertise (no formal laboratory 
training, as required for IEC) and no chemical manipulations or expensive consumable reagents or materials. 
These factors, combined with the possibility of rapid (and potentially ‘at the bedside’) throughput with modern 
room-temperature ATR-FTIR spectrometers, means that the FTIR method could provide a considerably more 
cost-effective means of urinary cystine detection (initial diagnosis) and quantitation (clinical management). This 
could allow more widespread patient screening for cystinuria and, of importance, provides a cost-effective means 
for frequent monitoring of insoluble patient urinary cystine variations during treatment, facilitating accurate 
assessment of disease severity and responses to treatment. Further enhancements of sensitivity and specificity 
could be achieved by inclusion of additional cystine bands (e.g. those at 845 and 775 cm−1) in the analytical 
algorithm or by more advanced quantitation methods using, for example, principal component analysis (PCA). 
Protocols could also be adapted for use with a high-throughput, automated transmission mode FTIR spectrome-
ter equipped with multi-sample silicon plates and extension to other stone-associated insoluble compounds such 
as oxalate and urate.
Methods
Patients and Materials. The study was performed in accordance with the relevant guidelines and regula-
tions for studies in human subjects and was approved by the Royal Free London NHS Foundation Trust Ethics 
Committee (R&D ref: 7727; REC number: 05/Q0508/6). Urine samples were collected in the outpatient clinic, as 
they are routinely, as mid-stream urine collections after obtaining informed consent for further research analysis, 
in addition to any routine clinical care analyses, from patients attending the Royal Free Hospital Metabolic Stone 
and Renal Service, London, UK; samples were stored at − 20 °C. Urine samples were obtained from 22 cystinuric 
patients, 5 healthy volunteer donors as controls, and (for creatinine analysis only) 11 additional patients with 
other renal conditions. All chemicals used were obtained from Sigma-Aldrich, Dorset, UK.
ATR-FTIR spectroscopy. Data were recorded with a dry air-purged Bruker IFS 66/S FTIR spectrometer 
operated with Bruker OPUS 6.5 software and fitted with a liquid nitrogen-cooled MCT-A detector, a KBr beam 
splitter and an ATR microprism (SensIR; 3-reflection silicon microprism with ZnSe optics). IR spectra were 
recorded at room temperature between 4000–750 cm−1. Typically, 500 interferograms at 4 cm−1 resolution were 
averaged (approx. 60s acquisition time) before Fourier transformation. Absorbance spectra were computed versus 
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a background power spectrum of the clean prism surface. Frequencies quoted have an accuracy of ~± 1 cm−1. 
Spectral contributions from water vapour in the optical path and (for samples in aqueous media) liquid water 
were removed by fractional subtraction of pure water vapour and liquid water reference spectra, respectively, with 
OPUS 6.5 software.
Quantitation of urea and creatinine by FTIR spectroscopy. Creatinine can be determined from IR 
spectra of whole urine with various deconvolution methods16–19,35. In the present study urea and creatinine were 
quantitated using the 1510–1445 cm−1 region of ATR-FTIR absorbance spectra of ‘as-collected’, undried urine 
since this region is dominated by urea and creatinine contributions35. For comparison, urinary creatinine was also 
assayed with the Jaffe reaction36, a protocol used in standard clinical practice. Details of methods are provided in 
Supplementary Information.
Quantitation of insoluble urinary cystine by ATR-FTIR spectroscopy. In order to increase 
the sensitivity of cystine detection to those relevant to cystinuria (several mM), a quantitative protocol was 
developed. Samples were dried onto the prism surface to form layers sufficiently thin that they did not fill the 
spectroscopically-active volume above the prism surface. A calibration plot was created by drying 5 μ L aliquots 
of 0 to 3 mM total (soluble + insoluble) L-cystine and measuring differences in intensities between 1296 cm−1 
and 1280 cm−1 of their second derivative spectra (details in Supplementary Information). A linear line of best fit 
through the origin with no error weighting was calculated using Origin 8.5 software (OriginLab, Northampton, 
MA, USA) for use as a calibration plot for urinary cystine concentrations.
Insoluble urinary material including cystine was separated from urea, creatinine and other solutes by 
centrifugation of 1 mL aliquots of the urine samples at 16000 gav for 40 minutes. Pellets were re-suspended in 1 mL 
double distilled water and thoroughly mixed by vortexing. 5 μ L aliquots were dried onto the prism surface and 
second derivative forms of absorbance spectra were recorded as described above. Insoluble cystine concentrations 
in the original urine samples were determined from the differences in intensities between 1296 and 1280 cm−1 in 
relation to the calibration plot. For validation, cystine concentrations in the same urine samples were also deter-
mined by IEC, the gold standard in clinical amino analysis7. Details are provided in Supplementary Information.
FTIR data validation. Bland-Altman plots32 were used to compare both the FTIR and Jaffe methods for 
quantitating creatinine, and the FTIR and IEC methods for quantitating cystine. The mean bias for each plot was 
calculated and plotted as a dashed line and 95% confidence limits (mean bias + /− 1.96 standard deviations) are 
indicated by dotted lines.
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